Meridian Bioscience (VIVO)

[stockvaper]

Meridian Bioscience Says New Covid-19 Sample Prep Eliminates Dependence on Reagents
BY Dow Jones & Company, Inc.
04/27/2020
Meridian Bioscience, Inc. (VIVO) said Monday it was launching "a novel enzyme master mix that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay."

The company said by eliminating the step, total assay cost is lower and processing times for Covid-19 samples can be cut by as much as 30 minutes a test.

"We have already shared this new master mix with nearly 20 early access laboratories around the globe, and their feedback has been quite positive," said Todd Howren, vice president of Global Sales at Meridian.